Sentiment-Signal
19,2
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 18.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint |
| 04.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ion 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Unternehmen & Branche
| Name | Indivior Pharmaceuticals, Inc. |
|---|---|
| Ticker | INDV |
| CIK | 0001625297 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,27 Mrd. USD |
| Beta | 1,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,239,000,000 | 210,000,000 | 1.64 | 1,201,000,000 | -98,000,000 |
| 2025-09-30 | 10-Q | 314,000,000 | 42,000,000 | 0.33 | 1,416,000,000 | -207,000,000 |
| 2025-06-30 | 10-Q | 302,000,000 | 18,000,000 | 0.14 | 1,452,000,000 | -257,000,000 |
| 2025-03-31 | 10-Q | 266,000,000 | 47,000,000 | 0.38 | 1,375,000,000 | -285,000,000 |
| 2024-12-31 | 10-Q | 21,000,000 | 0.05 | 1,316,000,000 | -337,000,000 | |
| 2024-12-31 | 10-K | 1,188,000,000 | 21,000,000 | 0.05 | 1,316,000,000 | -337,000,000 |
| 2024-09-30 | 10-K | 22,000,000 | ||||
| 2024-09-30 | 10-Q | 307,000,000 | 22,000,000 | 0.16 | -310,000,000 | |
| 2024-06-30 | 10-Q | 299,000,000 | -97,000,000 | -0.72 | -281,000,000 | |
| 2024-06-30 | 10-K | -97,000,000 | ||||
| 2024-03-31 | 10-K | 61,000,000 | ||||
| 2024-03-31 | 10-Q | 284,000,000 | 61,000,000 | 0.45 | -161,000,000 | |
| 2023-12-31 | 10-Q | -126,000,000 | -0.92 | 1,758,000,000 | -184,000,000 | |
| 2023-12-31 | 10-K | 1,093,000,000 | -126,000,000 | -0.92 | 1,758,000,000 | -184,000,000 |
| 2022-12-31 | 10-K | 901,000,000 | -44,000,000 | -0.32 | -15,000,000 | |
| 2022-12-31 | 10-Q | -42,000,000 | -0.30 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Ryan Barbara | Director | Open Market Purchase | 31 | 32.56 | 1,009.36 | +3,5% | |
| 2026-03-06 | Kingsley Stuart A | Director | Open Market Purchase | 940 | 31.87 | 29,953.10 | +103,1% | |
| 2026-01-05 | Humphreys Keith | Director | Open Market Purchase | 775 | 35.39 | 27,429.27 | +94,4% | |
| 2026-01-05 | Wheadon David E. | Director | Open Market Purchase | 1,771 | 35.39 | 62,680.29 | +215,8% | |
| 2026-01-05 | Stejbach Mark | Director | Open Market Purchase | 775 | 35.39 | 27,429.27 | +94,4% | |
| 2026-01-05 | NINIVAGGI DANIEL A | Director | Open Market Purchase | 775 | 35.39 | 27,429.27 | +94,4% | |
| 2026-01-05 | Ryan Barbara | Director | Open Market Purchase | 775 | 35.39 | 27,429.27 | +94,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.